---
title: How I Treat patients with AML using azacitidine and venetoclax
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39316723/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240925194758&v=2.18.0.post9+e462414
source: Blood
description: Venetoclax received full approval in October 2020 for use in older, unfit
  patients with acute myeloid leukemia (AML) combined with either hypomethylating
  agents or low-dose cytarabine. This ended a semi-centennial of stalled clinical
  progress and initiated a new treatment option with proven capacity to enhance response
  and prolong survival in older patients with AML. Despite widespread use of azacitidine-venetoclax
  (AZA-VEN), there is increasing appreciation that this regimen is ...
disable_comments: true
---
Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating agents or low-dose cytarabine. This ended a semi-centennial of stalled clinical progress and initiated a new treatment option with proven capacity to enhance response and prolong survival in older patients with AML. Despite widespread use of azacitidine-venetoclax (AZA-VEN), there is increasing appreciation that this regimen is ...